跳至主要内容
临床试验/NCT04585607
NCT04585607已完成4 期

Long-term Effects of Expanded Hemodialysis in Reduction of Large Middle Molecules in Chronic Hemodialysis Patients: Potential Benefits to the Prevention of Sarcopenia

Gangnam Severance Hospital1 个研究点 分布在 1 个国家目标入组 47 人开始时间: 2020年10月19日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
47
试验地点
1
主要终点
Biomarkers of sarcopenia

研究概览

简要总结

The current study will investigate whether long term implementation of expanded hemodialysis (HDx) will effectively decrease serum levels of large uremic toxins and ameliorate progression of sarcopenia in patients with chronic kidney disease requiring hemodialysis.

详细描述

This is an open-label, prospective, 1:1 randomized, parallel-group, study to evaluate the efficacy of expanded hemodialysis (HDx) compared to conventional hemodialysis in patients with chronic kidney disease in South Korea for up to 12 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • On HD treatment over 6 months before study enrollment
  • Aged over 18 years
  • Able to give informed consent

排除标准

  • Hemiplegia or paraplegia state
  • Planned renal transplant or conversion to peritoneal dialysis within study period
  • Active chronic infection or inflammatory conditions including autoimmune disease, inflammatory arthritis and active malignancy
  • History of monoclonal gammopathy
  • Life expectancy <12 months
  • Pregnancy or breast feeding
  • Receiving immunosuppressant medication
  • Inability to complete study assessments

结局指标

主要结局

Biomarkers of sarcopenia

时间窗: Changes in serum level of Myostatin and IGF-1 every 6 months

Change in blood levels of myostatin and insulin-like growth factor-1 (IGF-1)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hyeongcheon Park

Professor

Gangnam Severance Hospital

研究点 (1)

Loading locations...

相似试验